Nilotinib as first-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2011 Oct-Dec; 48(4): 438-445
Article
in English
| IMSEAR
| ID: sea-144524
ABSTRACT
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Piperazines
/
Pyrimidines
/
Protein-Tyrosine Kinases
/
Humans
/
Drug Resistance
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Disease-Free Survival
/
Molecular Targeted Therapy
/
Animals
/
Antineoplastic Agents
Language:
English
Journal:
Indian J Cancer
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS